11β-hydroxylase deficiency historical perspective
|
Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency Microchapters |
|
Differentiating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
11β-hydroxylase deficiency historical perspective On the Web |
|
American Roentgen Ray Society Images of 11β-hydroxylase deficiency historical perspective |
|
11β-hydroxylase deficiency historical perspective in the news |
|
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency |
|
Risk calculators and risk factors for 11β-hydroxylase deficiency historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Discovery
- Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency was first discovered by Dr. Walter Eberlein and Dr. Alfred M. Bongiovanni M.D, American physicians, in 1956 based on the study they conducted on accumulated steroids.[1]
Landmark Events in the Development of Treatment Strategies
Impact on Cultural History
Famous Cases
References
- ↑ BONGIOVANNI AM, EBERLEIN WR (1956). "Plasma and urinary corticosteroids in the hypertensive form of congenital adrenal hyperplasia". J Biol Chem. 223 (1): 85–94. PMID 13376579.